explore -WSS

explore

author：Wikipedia 2025-10-01 01:49:35 - browse：6899

Susan Galbraith of AstraZeneca gestures while speaking – pharma coverage from STAT — Susan Galbraith, AstraZeneca’s head of cancer research and development, speaks at a STAT event in 2023. Marie Miller for STAT

CHICAGO — AstraZeneca’s head of cancer research and development, Susan Galbraith, is British, and prone to a particularly British style of understatement. She doesn’t boast loudly. But she did come to this year’s annual meeting of the American Society of Clinical Oncology wearing a small lapel pin with the numeral 6 and the “AZ” corporate logo.

That pin represents the number of years in a row that the London-based drug giant has had a presentation in the ASCO plenary, the conference’s biggest showcase for new data. This year, the company has two.

Scientific credibility is great, of course. But AstraZeneca’s shareholders want something else: return on investment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Readout Newsletter: Merck, J&J, and long Covid

leisure time

focus

WSS

Biotech venture capitalists face new demands from investors

KalVista pill reduced swelling 'attacks' caused by genetic disease

EU regulator recommends expanding Mounjaro approval to obesity

What we’ve learned from the Aduhelm mess

What we’ve learned from the Aduhelm mess

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Wikipedia

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Guidelines to prevent youth baseball injuries need more muscle

To avoid data mishandling cases, universities eye AI and other tools

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

A disappointing year of Humira biosimilars

DIEP, the 'gold standard' of breast reconstruction, is under threat

Francis Collins on trust in science and how Covid communications failed

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Walensky prepares to leave CDC — and Congress — behind

Parkinson’s finding may lead to tests and, someday, treatments

explore

FDA clears AI tool for detecting skin cancer

'Revelatory' study finds a smoking impact that remains after quitting

FDA clears AI tool for detecting skin cancer

A disappointing year of Humira biosimilars

What we’ve learned from the Aduhelm mess

The Readout: Gilead, Bernie Sanders, and other pharma news

focus

leisure time

focus

hotspot